VANCE STREET CAPITAL LLC

Thesis

Vance Street Capital is a private equity firm founded in 2007, headquartered in Los Angeles, California. The firm specializes in acquiring and building "engineered solutions" companies, with a particular focus on technology-driven B2B businesses operating in regulated end markets. Vance Street Capital's investment strategy centers on control buyouts of North American industrial manufacturers and service providers, typically targeting companies with an EBITDA between $3 million and $30 million and enterprise values ranging from $30 million to $350 million. Their core investment thesis revolves around companies that are differentiated by strong intellectual property, niche manufacturing capabilities, operational know-how, and high barriers to entry. They actively seek businesses that solve difficult problems for blue-chip customers and are characterized by mission-critical components where the cost of failure is significant. The firm's preferred sectors include Medical Technology (Medtech), Life Sciences, Industrial Technology, and Aerospace and Defense. Vance Street Capital employs an operationally intensive strategy, focusing on control investments. Their approach involves leveraging a deep bench of experienced operators to implement initiatives such as LEAN Six-Sigma, quality/regulatory optimization, and sales strategy enhancement. The firm's typical investment scenarios include recapitalizations of family businesses, management buyouts, corporate carve-outs, and industry consolidations, as well as capital investment for strategic growth initiatives. Geographically, Vance Street Capital primarily invests in companies based in the United States and Canada. Vance Street Capital IV closed at $775 million in April 2024, bringing the firm's total capital commitments to over $2 billion. Vance Street Capital III closed at over $650 million i

Related lists

• Series C+ Enterprise investors
• Series C+ Healthcare investors
• Series C+ investors based in Los Angeles, CA